Table 2.

Univariate and multivariate analysis for relapse free survival in ER+/HER2− breast cancer patients

		Univariate			Mutivariate
		P‐value	HR	95% CI	P‐value	HR	95% CI
FGFR1 amplification	Normal
Normal	vs	0.92	0.94	0.22–2.73	0.90	1.10	0.21–4.26
Gain/amplification	Gain/amplification
FGFR1 mRNA expression
Low	Low versus high	0.40	0.68	0.25–1.64	0.39	0.62	0.19–1.76
High
FGFR1 protein expression
Low	Low versus high	0.019*	2.63	1.17–5.98	0.0070*	3.63	1.42–9.95
High
Age
<50	<50 vs ≥50	0.062	0.45	0.20–1.04	0.032*	0.11	0.017–0.83
≥50
Menstrual status
Premenopause	Pre versus post	0.38	0.69	0.31–1.64	0.095	5.82	0.74–39.53
Postmenopause
BMI
<23	<23 vs ≥23	0.96	1.02	0.43–2.37	0.64	1.25	0.48–3.29
≥23
Nuclear grade
1	1 vs 2, 3	0.71	1.17	0.50–2.62	0.50	0.70	0.23–1.96
2, 3
Tumor invasion size	≤20 mm
≤20 mm	vs	0.16	1.78	0.80–4.13	0.48	1.43	0.53–4.01
>20 mm	>20 mm
Nodal status
+	+ vs −	0.078	2.07	0.92‐4.70	0.43	1.48	0.51–4.08
−
Ki67
<15%	<15% vs ≥15%	0.092	2.23	0.88–6.79	0.45	1.51	0.53–4.95
≥15%

*χ²‐test: P < 0.05. BMI, body mass index; CI, confidence interval; ER+/HER2−, estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative; FGFR1, fibroblast growth factor receptor‐1; HR, hazard ratio.